Home Healthcare  Summary QuidelOrtho's core lab testing and immunohematology businesses account for over 75% of sales, where customers sign 5-7-year contracts and the company boasts a contract renewal rate exceeding 95%. While QuidelOrtho missed its 2025 free cash flow guidance due to accounts receivable issues, the company successfully recovered roughly half of that increase during the first quarter. Management models the Chinese reimbursement policy change as a $70 million EBITDA hit, with the impact felt almost entirely in the next 18 months. QuidelOrtho believes LEX has a strong chance of turning the company's respiratory business back into a growth engine after losing share to rival molecular diagnostics competitors. QuidelOrtho retains substantial flexibility to address debt, such as selling the immunohematology division or exiting its capital-intensive leasing business to reduce leverage.…